Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
Elevation Oncology表示，截至2024年3月31日，現金、現金等價物和有價證券爲1.041億美元，外加2024年第一季度之後在自動櫃員機融資機制下籌集的1450萬美元淨收益，足以爲其2026年的當前業務提供資金
Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
Elevation Oncology表示，截至2024年3月31日，現金、現金等價物和有價證券爲1.041億美元，外加2024年第一季度之後在自動櫃員機融資機制下籌集的1450萬美元淨收益，足以爲其2026年的當前業務提供資金
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。